|
|
Article: BioLineRx's BL-1040 Named One of 10 Most Promising Cardiovascular Projects by Windhover.
- Article from:
- Business Wire
- Article date:
- July 16, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
JERUSALEM -- BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, announced today that BL-1040, a novel myocardial implant for the treatment of acute myocardial infarction (MI), has been selected as one of the Top 10 most promising cardiovascular projects in development available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our ...